Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology

Canadian Journal of Cardiology

Volumn 25, Issue 9, 2009, Pages 523-526

  Li, Ming Jiang ^a   Huang, C X ^a   Okello, E ^a   Yanhong, T ^a   Mohamed, S ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

ICM; ICTP; MMPs; PICP; Spironolactone; TIMPs

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; GELATINASE B; SPIRONOLACTONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; DIURETIC AGENT; MATRIX METALLOPROTEINASE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL ASSESSMENT; COLLAGEN METABOLISM; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEART FAILURE; HEART FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DIASTOLE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; FOLLOW UP; HEART CONTRACTION; HEART MUSCLE ISCHEMIA; HEART STROKE VOLUME; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SYSTOLE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; DIASTOLE; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; SPIRONOLACTONE; STROKE VOLUME; SYSTOLE; TREATMENT OUTCOME;

EID: 70349561834     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(09)70138-2     Document Type: Article

References (16)

1. Schwartzkopff B, Fassbach M, Pelzer B, Brehm M, Strauer BE. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 2002;4:439-44.
2. Lombardi R, Betocchi S, Losi MA, et al. Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation 2003;108:1455-60.
3. Blankenberg S, Rupprecht HJ, Poirier O, et al; AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-85.
4. Spinale FG, Coker ML, Heung LJ, et al. A matrix metalloprotienase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000;102:1944-9.
5. Wilson EM, Gunasinghe HR, Coker ML, et al. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail 2002;8:390-8.
6. Mukherjee D, Sen S. Alteration of collagen phenotypes in ischemic cardiomyopathy. J Clin Invest 1991;88:1141-6.
7. Tyagi SC, Kumar SG, Haas SJ, et al. Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. J Mol Cell Cardiol 1996;28:1415-28.
8. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ III, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardiurn from patients with end-stage dilated cardiomyopathy. Circulation 1998;97:1708-15.
9. Li YY, McTiernan CF, Feldman AM. Interplay of matrix meralloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 2000;46:214-24.
10. Li YY, Feldman AM, Sun Y, McTiernan CF. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998;98:1728-34.
11. Lijnen P, Petrov V. Antagonism of the renin-angiotensin-aldosterone system and collagen metabolism in cardiac fibroblasts. Methods Find Exp Clin Pharmacol 1999;21:215-27.
12. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the Randomized Aldactone Evaluation Study (RALES). Rates Investigators. Circulation 2000;102:2700-6.
13. Jung K. Sample processing and its preanalytical impact on the measurement of circulating matrix metalloproteinases. Clin Chem Lab Med 2006;44:500-2.
14. Hein S, Schaper J. The extracellular matrix in normal and diseased myocardium. J Nucl Cardiol 2001;8:188-96.
15. Eber KT. Aldosterone and spironolactone in heart failure. N Engl J Med 1999;341:753-4.
16. Zannad F. Angiotensin-converting enzyme inhibitor and spironolactone combination therapy: New objectives in congestive heart failure treatment. Am J Cardiol 1993;71:34A-39A.